UTHR Stock UPDATES United Therapeutics Corp (UTHR) 127.61 10/22/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 7:15 AM

United Therapeutics Corp (UTHR) 127.61 $UTHR

United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014
PR Newswire - Tue Oct 21, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2014 financial results before market open on Tuesday, October 28, 2014.
UTHR: 127.61 (+1.15)

Creator of GeoStar and Sirius Radio, Martine Rothblatt to speak at the Church of Perpetual Life
PR Newswire - Mon Oct 20, 3:06PM CDT
Join the Church of Perpetual Life for a special presentation with Martine Rothblatt. She will be discussing the Terasem Movement which she launched in 2004. It is a transhumanist school of thought movement focused on promoting joy, diversity and the prospect of technological immortality via mind uploading and geoethical nanotechnology.
UTHR: 127.61 (+1.15)

Should Ebola Fear... Tobacco?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 19, 11:15AM CDT
Source: Medicago In 2009, the Department of Defense's Defense Advanced Research Projects Agency, or DARPA, had a problem on its hands. The swine flu was spreading and policy makers were realizing that the current methods for producing vaccines...
RAI: 61.03 (+1.90), PM: 87.45 (+0.52), UTHR: 127.61 (+1.15), SRPT: 22.49 (-0.34), TKMR: 17.98 (-0.63), GSK: 43.63 (+0.02)

Upgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Oct 16, 7:16AM CDT
United Therapeutics (NASDAQ:UTHR) was upgraded from Hold to Buy at Standpoint Research today. The stock closed yesterday at $124.04 on volume of 957,000 shares, below average daily volume of 1.1 million. Over the past year, United Therapeutics has traded in a range of $36.55 to $136.93 and closed yesterday at $124.04, 239% above that low. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 1.8%.
UTHR: 127.61 (+1.15)

Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 11.79 (+0.11), UTHR: 127.61 (+1.15), PCRX: 100.85 (+1.94), HPTX: 22.75 (+0.08)

J&J Beats Q3 Earnings on Strong Drug Sales, Ups View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Oct 14, 10:27AM CDT
Johnson & Johnson's (JNJ) Pharmaceutical segment continued to deliver with new products like Olysio (HCV) putting in an impressive performance.
AGN: 186.16 (+6.91), JNJ: 100.36 (+1.16), SHPG: 185.80 (+1.21), UTHR: 127.61 (+1.15)

Shares of UTHR Up 39.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 09, 9:44AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 2 months, United Therapeutics has returned 39.74% as of today's recent price of $130.44.
UTHR: 127.61 (+1.15)

United Therapeutics Rises 1.43% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Oct 08, 5:32PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $129.07 to a high of $132.96. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $132.13 on volume of 969,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 127.61 (+1.15)

Upcoming Events, New Facilities, Technical Updates, and Pilot Programs - Research Reports on Aetna, United Therapeutics, Quest Diagnostics, Cummins and Danaher
PR Newswire - Wed Oct 08, 7:30AM CDT
Today, Analysts Review released its research reports regarding Aetna Inc. (NYSE: AET), United Therapeutics Corporation (NASDAQ: UTHR), Quest Diagnostics Inc. (NYSE: DGX), Cummins Inc. (NYSE: CMI) and Danaher Corp. (NYSE: DHR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7007-100free.
CMI: 134.80 (+3.92), DGX: 61.12 (+1.47), UTHR: 127.61 (+1.15), DHR: 76.25 (+1.52), AET: 78.39 (+1.94)

Shares of UTHR Up 40.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 02, 9:19AM CDT
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on August 19th, 2014 at $93.35. In approximately 1 month, United Therapeutics has returned 39.96% as of today's recent price of $130.65.
UTHR: 127.61 (+1.15)

United Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 3.06%
Comtex SmarTrend(R) - Tue Sep 30, 5:06PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $128.53 to a high of $134.99. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $131.84 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 127.61 (+1.15)

United Therapeutics Falls 3.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Sep 30, 5:06PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $128.53 to a high of $134.99. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $131.84 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 127.61 (+1.15)

Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics
PR Newswire - Thu Sep 25, 8:20AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and United Therapeutics Corporation (NASDAQ: UTHR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6765-100free.
VRX: 130.38 (+5.60), UTHR: 127.61 (+1.15), TKMR: 17.98 (-0.63), TEVA: 53.26 (+1.57), REGN: 381.01 (+14.88), VRX.TO: 146.47 (+5.73)

Can the Uptrend Continue for United Therapeutics (UTHR)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 9:34AM CDT
Can the Uptrend Continue for United Therapeutics (UTHR)?
UTHR: 127.61 (+1.15)

Moving Average Crossover Alert: United Therapeutics (UTHR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 8:09AM CDT
Moving Average Crossover Alert: United Therapeutics (UTHR)
UTHR: 127.61 (+1.15)

Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Tue Sep 23, 6:56AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Standpoint Research today. The stock closed yesterday at $133.68 on volume of 1.5 million shares, above average daily volume of 986,000. In the past 52 weeks, shares of United Therapeutics have traded between a low of $36.55 and a high of $134.19 and closed yesterday at $133.68, which is 266% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.6% while the 50-day MA has advanced 2.3%.
UTHR: 127.61 (+1.15)

Watch for United Therapeutics to Potentially Pullback After Gaining 2.74% Yesterday
Comtex SmarTrend(R) - Mon Sep 22, 5:37PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $128.34 to a high of $134.19. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $131.97 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 127.61 (+1.15)

Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 2.74% Rise
Comtex SmarTrend(R) - Mon Sep 22, 5:36PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $128.34 to a high of $134.19. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $131.97 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 127.61 (+1.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...